With headquarters and manufacturing facilities in Shenyang, 3SBio addresses unmet medical needs in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. As one of China's largest biotech drugmakers, it reported a revenue of CNY 6.3 billion in 2021. Their core drugs, TPIAO, Yisaipu, rhEPO, and Mandi, contribute to around 90% of their revenue. While most pipeline candidates are "me-too" drugs at an early stage, 3SBio remains focused on serving large markets with significant medical needs.